Evaluate Vantage puts Novo Nordisk drug on list of most promising biologics
According to the research company Evaluate Vantage, Novo Nordisk has good reason to have confidence in likely successor to semaglutide, cagrisema.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.